Özlem Gül Utku
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Özlem Gül Utku has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Bilal Ergül
Department of Gastroenterology, Lokman Hekim University Faculty of Medicine, Ankara, Türkiye
10 shared publications - Dilek Oğuz
Department of Gastroenterology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey
9 shared publications - Eylem Karatay
Department of Internal Medicine, İstinye University Faculty of Medicine, İstanbul, Türkiye
7 shared publications - Göksel Bengi
Department of Gastroenterology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye
3 shared publications - Harun Erdal
Department of Gastroenterology, Ankara Etlik City Hospital, University of Health Sciences, Ankara, Türkiye
3 shared publications - Müjde Soytürk
Department of Gastroenterology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye
3 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in BMC Gastroenterology
Histological upgrading from pre-ESD biopsy to resection and endoscopic curability after gastric ESD: a multicenter retrospective cohort study
Background: Endoscopic submucosal dissection (ESD) enables organ-preserving treatment of gastric epithelial neoplasia while providing definitive histopathological assessment for subsequent risk stratification. Aims: To evaluate multicenter clinical, technical, and histopathological outcomes of gastric ESD, assess histological concordance between pre-ESD biopsy and resection specimens, identify factors associated with histological upgrading, and characterize endoscopic curability according to the 2025 eCura criteria. Methods: This multicenter retrospective cohort included 89 patients with 89 gastric epithelial neoplasms treated by ESD at three tertiary centers between January 2023 and January 2026. Histological concordance was assessed using the revised Vienna classification, and factors associated with upgrading were evaluated using Firth penalized logistic regression. Results: En bloc and R0 resection rates were 94.4% and 84.3%, respectively. Post-ESD complications occurred in 10.1% of patients, including delayed bleeding in 9.0%, with no perforations. Among 70 lesions with pre-ESD biopsy, 29 (41.4%) were upgraded and one (1.4%) was downgraded. Increasing age (aOR 1.92 per 10 years; 95% CI 1.06–3.81) and lesion size (aOR 1.74 per 10 mm; 95% CI 1.04–3.07) were associated with upgrading. Among 30 carcinomas, 16 (53.3%) fulfilled the 2025 eCura criteria for curative resection, while six lesions classified as eCuraB under the 2021 criteria were reclassified as eCuraA. Conclusions: In this multicenter cohort, gastric ESD achieved high en bloc and R0 resection rates with an acceptable safety profile. Histological upgrading after pre-ESD biopsy was common, particularly with increasing age and lesion size, underscoring the importance of definitive ESD histopathology for accurate assessment of endoscopic curability.
- 12 November 2026
- Published by Springer Nature in BMC Gastroenterology
Open AccessHistological upgrading from pre-ESD biopsy to resection and endoscopic curability after gastric ESD: a multicenter retrospective cohort study
Background: Endoscopic submucosal dissection (ESD) enables organ-preserving treatment of gastric epithelial neoplasia while providing definitive histopathological assessment for subsequent risk stratification. Aims: To evaluate multicenter clinical, technical, and histopathological outcomes of gastric ESD, assess histological concordance between pre-ESD biopsy and resection specimens, identify factors associated with histological upgrading, and characterize endoscopic curability according to the 2025 eCura criteria. Methods: This multicenter retrospective cohort included 89 patients with 89 gastric epithelial neoplasms treated by ESD at three tertiary centers between January 2023 and January 2026. Histological concordance was assessed using the revised Vienna classification, and factors associated with upgrading were evaluated using Firth penalized logistic regression. Results: En bloc and R0 resection rates were 94.4% and 84.3%, respectively. Post-ESD complications occurred in 10.1% of patients, including delayed bleeding in 9.0%, with no perforations. Among 70 lesions with pre-ESD biopsy, 29 (41.4%) were upgraded and one (1.4%) was downgraded. Increasing age (aOR 1.92 per 10 years; 95% CI 1.06–3.81) and lesion size (aOR 1.74 per 10 mm; 95% CI 1.04–3.07) were associated with upgrading. Among 30 carcinomas, 16 (53.3%) fulfilled the 2025 eCura criteria for curative resection, while six lesions classified as eCuraB under the 2021 criteria were reclassified as eCuraA. Conclusions: In this multicenter cohort, gastric ESD achieved high en bloc and R0 resection rates with an acceptable safety profile. Histological upgrading after pre-ESD biopsy was common, particularly with increasing age and lesion size, underscoring the importance of definitive ESD histopathology for accurate assessment of endoscopic curability.
- 31 August 2026
- Published by MediHealth Academy in Intercontinental Journal of Internal Medicine
- Vol. 4 (3) , 65-71
Changes in anthropometric and metabolic parameters related to gastroesophageal reflux disease in non obese cases
Aims: Central obesity associated with visceral adiposity is considered to increase reflux symptoms. This study aimed to investigate the effects of anthropometric and visceral fat-related measurements on reflux symptoms in non-obese patients with gastroesophageal reflux disease (GERD) and a body mass index (BMI) <30. Methods: The study included 120 non-obese patients with dyspeptic complaints, BMI <30, and GERD diagnosed according to the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (FSSG), and 50 non-obese controls with BMI <30, no dyspeptic complaints, and no GERD according to the FSSG. Demographic data and extraesophageal symptoms were assessed using a questionnaire. Serum biochemical findings were recorded. Body composition and anthropometric measurements were evaluated using bioelectrical impedance analysis (TANITA). Results: Significant differences were found between the GERD and healthy control groups in waist circumference, BMI, low-density lipoprotein cholesterol (LDL), body fat percentage, fat mass, total body water (TBW), metabolic age, visceral fat, obesity grade, reflux score, acid reflux score, and total FSSG score (p<0.05). Sore throat, apnea, and teeth grinding also differed significantly between the groups (p<0.05). In the patient group, acid reflux scores were positively correlated with BMI (r=0.298, p=0.001), LDL (r=0.387, p<0.001), and visceral fat (r=0.180, p=0.049), and negatively correlated with TBW (r=-0.273, p<0.003). Conclusion: Reflux symptom frequency and severity are closely associated with body fat composition in non-obese as well as obese patients. Increased abdominal and visceral fat may increase GERD risk independently of obesity.
- 31 August 2026
- Published by MediHealth Academy in Intercontinental Journal of Internal Medicine
- Vol. 4 (3) , 65-71
Changes in anthropometric and metabolic parameters related to gastroesophageal reflux disease in non obese cases
Aims: Central obesity associated with visceral adiposity is considered to increase reflux symptoms. This study aimed to investigate the effects of anthropometric and visceral fat-related measurements on reflux symptoms in non-obese patients with gastroesophageal reflux disease (GERD) and a body mass index (BMI) <30. Methods: The study included 120 non-obese patients with dyspeptic complaints, BMI <30, and GERD diagnosed according to the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (FSSG), and 50 non-obese controls with BMI <30, no dyspeptic complaints, and no GERD according to the FSSG. Demographic data and extraesophageal symptoms were assessed using a questionnaire. Serum biochemical findings were recorded. Body composition and anthropometric measurements were evaluated using bioelectrical impedance analysis (TANITA). Results: Significant differences were found between the GERD and healthy control groups in waist circumference, BMI, low-density lipoprotein cholesterol (LDL), body fat percentage, fat mass, total body water (TBW), metabolic age, visceral fat, obesity grade, reflux score, acid reflux score, and total FSSG score (p<0.05). Sore throat, apnea, and teeth grinding also differed significantly between the groups (p<0.05). In the patient group, acid reflux scores were positively correlated with BMI (r=0.298, p=0.001), LDL (r=0.387, p<0.001), and visceral fat (r=0.180, p=0.049), and negatively correlated with TBW (r=-0.273, p<0.003). Conclusion: Reflux symptom frequency and severity are closely associated with body fat composition in non-obese as well as obese patients. Increased abdominal and visceral fat may increase GERD risk independently of obesity.
- Open Access
- 11 August 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Revisiting the Gray Zone in HBeAg-Negative Chronic Hepatitis B: Insights From a Multicenter Liver Biopsy Cohort
Background/Aims: The management of patients with HBeAg-negative chronic hepatitis B (CHB) with intermediate viremia and persistently normal alanine aminotransferase (ALT) levels remains controversial. This “gray-zone” (GZ) population may harbor significant histological liver injury despite not meeting conventional treatment criteria. This study characterized the histologic features of this GZ population and compared their clinical and laboratory characteristics. Materials and Methods: In this multicenter retrospective study, patients with HBeAg negative CHB who had hepatitis B virus (HBV) DNA levels between 2000 and 20 000 IU/mL and persistently normal ALT levels and who underwent liver biopsy between 2014 and 2022 were included. Histological assessment was performed using the modified Ishak scoring system. Significant fibrosis was defined as Ishak stage of 2 or greater. Clinical, virological, and noninvasive fibrosis parameters were analyzed. Results: A total of 145 patients were included (mean age: 46.3 ± 12.6 years; 54.5% female). Significant fibrosis and/or moderate-tosevere necroinflammatory activity requiring antiviral therapy was identified in 109 patients (75.1%). Although ALT and aspartate aminotransferase levels remained within normal reference range, both were significantly higher in the treatment group compared than in the nontreatment group (P = .003 and P = .018, respectively). Aspartate aminotransferase-to-platelet ration index (APRI) scores were also significantly elevated among treated patients (P = .02), whereas Fibrorsis-4 (FIB-4) scores did not differ significantly. HBV DNA and quantitative Hepatitis B surface antigen (HBsAg) levels were comparable between groups. Conclusion: A substantial proportion of patients with HBeAg-negative CHB in the GZ exhibited clinically significant histologic disease despite persistently normal ALT levels. Reliance solely on conventional biochemical thresholds may underestimate the burden of fibrosis. Early histological evaluation and more proactive treatment strategies should be considered for selected patients in the GZ. Cite this article as: Gül Ö, Köseoğlu H, Yalçın S, et al. Revisiting the gray zone in HBeAg negative chronic hepatitis B: Insights from a multicenter liver biopsy cohort. Turk J Gastroenterol. Published online August 11, 2026. doi: 10.5152/tjg.2026.26367.
- 11 August 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Open AccessRevisiting the Gray Zone in HBeAg-Negative Chronic Hepatitis B: Insights From a Multicenter Liver Biopsy Cohort
Background/Aims: The management of patients with HBeAg-negative chronic hepatitis B (CHB) with intermediate viremia and persistently normal alanine aminotransferase (ALT) levels remains controversial. This “gray-zone” (GZ) population may harbor significant histological liver injury despite not meeting conventional treatment criteria. This study characterized the histologic features of this GZ population and compared their clinical and laboratory characteristics. Materials and Methods: In this multicenter retrospective study, patients with HBeAg negative CHB who had hepatitis B virus (HBV) DNA levels between 2000 and 20 000 IU/mL and persistently normal ALT levels and who underwent liver biopsy between 2014 and 2022 were included. Histological assessment was performed using the modified Ishak scoring system. Significant fibrosis was defined as Ishak stage of 2 or greater. Clinical, virological, and noninvasive fibrosis parameters were analyzed. Results: A total of 145 patients were included (mean age: 46.3 ± 12.6 years; 54.5% female). Significant fibrosis and/or moderate-tosevere necroinflammatory activity requiring antiviral therapy was identified in 109 patients (75.1%). Although ALT and aspartate aminotransferase levels remained within normal reference range, both were significantly higher in the treatment group compared than in the nontreatment group (P = .003 and P = .018, respectively). Aspartate aminotransferase-to-platelet ration index (APRI) scores were also significantly elevated among treated patients (P = .02), whereas Fibrorsis-4 (FIB-4) scores did not differ significantly. HBV DNA and quantitative Hepatitis B surface antigen (HBsAg) levels were comparable between groups. Conclusion: A substantial proportion of patients with HBeAg-negative CHB in the GZ exhibited clinically significant histologic disease despite persistently normal ALT levels. Reliance solely on conventional biochemical thresholds may underestimate the burden of fibrosis. Early histological evaluation and more proactive treatment strategies should be considered for selected patients in the GZ. Cite this article as: Gül Ö, Köseoğlu H, Yalçın S, et al. Revisiting the gray zone in HBeAg negative chronic hepatitis B: Insights from a multicenter liver biopsy cohort. Turk J Gastroenterol. Published online August 11, 2026. doi: 10.5152/tjg.2026.26367.
- Open Access
- 21 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (5) , 534-554
Clinical Practice Update on the Evaluation, Diagnosis, and Management of Pancreatic Exocrine Insufficiency: Expert Review
Pancreatic exocrine insufficiency (PEI) is characterized by inadequate synthesis, secretion, and/or activation of exocrine pancreatic secretions. This guideline has been developed to assist clinicians and researchers in understanding the definition, etiopathogenesis, epidemiology, diagnosis, treatment, and follow-up of PEI based on the current literature. All statements within this review were developed through consensus among the authors based on a comprehensive literature review. Cite this article as: Sezgin O, Oğuz D, Soytürk M, Kalkan İH, Bengi G, Gül .. Clinical practice update on the evaluation, diagnosis, and management of pancreatic exocrine insufficiency: Expert review. Turk J Gastroenterol. Published online April 21, 2026. doi: 10.5152/tjg.2026.25679.
- 21 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (5) , 534-554
Open AccessClinical Practice Update on the Evaluation, Diagnosis, and Management of Pancreatic Exocrine Insufficiency: Expert Review
Pancreatic exocrine insufficiency (PEI) is characterized by inadequate synthesis, secretion, and/or activation of exocrine pancreatic secretions. This guideline has been developed to assist clinicians and researchers in understanding the definition, etiopathogenesis, epidemiology, diagnosis, treatment, and follow-up of PEI based on the current literature. All statements within this review were developed through consensus among the authors based on a comprehensive literature review. Cite this article as: Sezgin O, Oğuz D, Soytürk M, Kalkan İH, Bengi G, Gül .. Clinical practice update on the evaluation, diagnosis, and management of pancreatic exocrine insufficiency: Expert review. Turk J Gastroenterol. Published online April 21, 2026. doi: 10.5152/tjg.2026.25679.
- 25 February 2026
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 4 (1) , 1-6
Are decreased serum Maresin 1 levels predictive of cholangiocarcinoma?
Aims: Cholangiocarcinoma (CC) is a rare form of adenocarcinoma originating from the epithelial cells of the biliary tract. Chronic inflammation is known to be a risk factor for this tumor. The present study aimed to investigate whether serum levels of Maresin 1 (MaR1) (a macrophage-derived anti-inflammatory lipid mediator) were associated with the presence of benign biliary disease (BBD) or CC. Methods: The study was conducted with 104 participants, including 42 patients with CC, 32 patients with BBD, and 30 volunteers without any hepatobiliary pathology. Blood samples were taken from each participant, and serum MaR1 levels were measured with enzyme-linked immunosorbent assay kits. Results: Serum MaR1 levels were significantly lower in the CC and BBD groups compared to controls (p < 0.001, for both); however, there was no significant difference between the CC and BBD groups in terms of MaR1 level (p > 0.05). The cancer antigen (CA) 19-9 and carcinoembryonic antigen (CEA) values of the CC group were found to be significantly higher than the BBD and control groups (p < 0.001, for both). Although MaR1 was found to have diagnostic value in differentiating patients with CC or BBD from controls, it had no value in distinguishing CC from BBD; whereas CA19-9 and CEA had significant discriminatory power. Conclusion: Decreased serum MaR1 level may predict inflammation in hepatobiliary pathologies such as CC and BBD; however, it cannot be used to discriminate CC from BBD, and classical cancer markers such as CA19-9 and CEA appear to retain superiority in this respect.
- 25 February 2026
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 4 (1) , 1-6
Are decreased serum Maresin 1 levels predictive of cholangiocarcinoma?
Aims: Cholangiocarcinoma (CC) is a rare form of adenocarcinoma originating from the epithelial cells of the biliary tract. Chronic inflammation is known to be a risk factor for this tumor. The present study aimed to investigate whether serum levels of Maresin 1 (MaR1) (a macrophage-derived anti-inflammatory lipid mediator) were associated with the presence of benign biliary disease (BBD) or CC. Methods: The study was conducted with 104 participants, including 42 patients with CC, 32 patients with BBD, and 30 volunteers without any hepatobiliary pathology. Blood samples were taken from each participant, and serum MaR1 levels were measured with enzyme-linked immunosorbent assay kits. Results: Serum MaR1 levels were significantly lower in the CC and BBD groups compared to controls (p < 0.001, for both); however, there was no significant difference between the CC and BBD groups in terms of MaR1 level (p > 0.05). The cancer antigen (CA) 19-9 and carcinoembryonic antigen (CEA) values of the CC group were found to be significantly higher than the BBD and control groups (p < 0.001, for both). Although MaR1 was found to have diagnostic value in differentiating patients with CC or BBD from controls, it had no value in distinguishing CC from BBD; whereas CA19-9 and CEA had significant discriminatory power. Conclusion: Decreased serum MaR1 level may predict inflammation in hepatobiliary pathologies such as CC and BBD; however, it cannot be used to discriminate CC from BBD, and classical cancer markers such as CA19-9 and CEA appear to retain superiority in this respect.
- Open Access
- 30 January 2025
- Published by MediHealth Academy in Journal of Radiology in Medicine
- Vol. 2 (1) , 1-5
Comparison of percutaneous liver aspiration biopsy and tru-cut biopsy results
Aims: The aim of this study was to compare the diagnostic rates, complications and histopathologic diagnoses of aspiration biopsy and tru-cut biopsy procedures in liver parenchyma and to reveal the differences between the technical methods. Methods: Patients who underwent liver parenchymal biopsy in our hospital were identified. While tru-cut biopsy needle was used in the radiology department, aspiration biopsy needle was used in the gastroenterology department. Patients who underwent parenchymal biopsy were included in the study, while lesion biopsies were excluded. Indications for biopsy, presence of hepatitis, type of biopsy needle, number of times, size of biopsy material, pathologic diagnosis and complications after biopsy were evaluated. Results: Of the 113 patients who underwent liver biopsy, 74 were male (mean age 40.38.±17.37 years) and 39 were female (mean age 45.49±15.85 years). Among the patients who underwent liver biopsy, tru-cut biopsy needle was used in 46 patients, while aspiration biopsy needle was used in 67 patients. The biopsy size and number of pieces were statistically significantly higher in aspiration biopsy compared to tru-cut biopsy. There was no difference between the two biopsies in terms of diagnosis rate, complication development, fibrosis staging and score. Conclusion: Percutaneous aspiration and tru-cut biopsies are reliable diagnostic methods with high diagnostic rates and low complication rates. The fact that biopsy is performed by experienced hands, under US guidance, and the number of biopsies is limited reduces the development of complications.
- 30 January 2025
- Published by MediHealth Academy in Journal of Radiology in Medicine
- Vol. 2 (1) , 1-5
Open AccessComparison of percutaneous liver aspiration biopsy and tru-cut biopsy results
Aims: The aim of this study was to compare the diagnostic rates, complications and histopathologic diagnoses of aspiration biopsy and tru-cut biopsy procedures in liver parenchyma and to reveal the differences between the technical methods. Methods: Patients who underwent liver parenchymal biopsy in our hospital were identified. While tru-cut biopsy needle was used in the radiology department, aspiration biopsy needle was used in the gastroenterology department. Patients who underwent parenchymal biopsy were included in the study, while lesion biopsies were excluded. Indications for biopsy, presence of hepatitis, type of biopsy needle, number of times, size of biopsy material, pathologic diagnosis and complications after biopsy were evaluated. Results: Of the 113 patients who underwent liver biopsy, 74 were male (mean age 40.38.±17.37 years) and 39 were female (mean age 45.49±15.85 years). Among the patients who underwent liver biopsy, tru-cut biopsy needle was used in 46 patients, while aspiration biopsy needle was used in 67 patients. The biopsy size and number of pieces were statistically significantly higher in aspiration biopsy compared to tru-cut biopsy. There was no difference between the two biopsies in terms of diagnosis rate, complication development, fibrosis staging and score. Conclusion: Percutaneous aspiration and tru-cut biopsies are reliable diagnostic methods with high diagnostic rates and low complication rates. The fact that biopsy is performed by experienced hands, under US guidance, and the number of biopsies is limited reduces the development of complications.
- Open Access
- 15 November 2024
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 35 (Supplement) , S1-S44
Turkish Society of Gastroenterology: Pancreas Working Group, Acute Pancreatitis Committee Consensus Report
Acute pancreatitis (AP) is a clinical condition that arises acutely in the pancreas through various inflammatory pathways due to multiple causes. Turkish Society of Gastroenterology Pancreas Working Group developed comprehensive guidance statements regarding the management of AP that include its epidemiology, etiology, clinical presentation, diagnostic criteria, disease severity, treatment, prognosis, local and systemic complications. The statements were developed through literature review, deliberation, and consensus opinion. These statements were ultimately used to develop a conceptual framework for the multidisciplinary management of AP. Cite this article as: Öğütmen Koç D, Bengi G, Gül Ö, et al. Turkish society of gastroenterology: Pancreas working group, acute pancreatitis committee consensus report. Turk J Gastroenterol. 2024;35(S1):S1-S44.
- 15 November 2024
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 35 (Supplement) , S1-S44
Open AccessTurkish Society of Gastroenterology: Pancreas Working Group, Acute Pancreatitis Committee Consensus Report
Acute pancreatitis (AP) is a clinical condition that arises acutely in the pancreas through various inflammatory pathways due to multiple causes. Turkish Society of Gastroenterology Pancreas Working Group developed comprehensive guidance statements regarding the management of AP that include its epidemiology, etiology, clinical presentation, diagnostic criteria, disease severity, treatment, prognosis, local and systemic complications. The statements were developed through literature review, deliberation, and consensus opinion. These statements were ultimately used to develop a conceptual framework for the multidisciplinary management of AP. Cite this article as: Öğütmen Koç D, Bengi G, Gül Ö, et al. Turkish society of gastroenterology: Pancreas working group, acute pancreatitis committee consensus report. Turk J Gastroenterol. 2024;35(S1):S1-S44.
- Open Access
- 15 September 2024
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 35 (9) , 735-742
Validity and Diagnostic Ability of Pancreatic Exocrine Insufficiency Questionnaire in Turkish Patients
Background/Aims: Pancreatic exocrine insufficiency (PEI) is a prevalent disease that is often underdiagnosed and undertreated, leading to resulting in diminished health-related quality of life. The PEI questionnaire (PEI-Q), a patient-reported outcome questionnaire developed to diagnose and evaluate PEI, is available only in English. The study aimed to provide a Turkish translation of PEI-Q and validate its reliability and diagnostic performance in a Turkish-speaking population with PEI. Materials and Methods: This study included 161 participants: 98 patients with PEI and 63 healthy controls. Participants underwent the PEI-Q test, and the results were statistically analyzed for reliability and validity. The diagnostic value of PEI-Q was determined using receiver operating characteristic (ROC) curves. Cronbach’s alpha was used to assess internal consistency, while exploratory factor analysis was performed to determine construct validity and reveal the factor structure. Results: The mean age of participants was 45.0 years, and 60.2% were male. Participants with PEI were significantly older than those without. Scores for abdominal, bowel movement, and total symptoms were significantly higher in patients with PEI than in controls. ROC analysis revealed good diagnostic value for PEI-Q, with areas under the curve ranging from 0.798 to 0.851 for different symptom scores. Cronbach’s alpha coefficients were above 0.70, indicating good internal consistency, and exploratory factor analysis supported a 4-factor structure, accounting for 68.9% of the total variance. Conclusion: The Turkish version of the PEI-Q is a reliable, easy-to-use, and valid screening tool for diagnosing PEI. It consistently assesses symptoms and quality of life in patients with PEI, helping to inform diagnosis and treatment. Cite this article as: Oğuz D, Kalkan İH, Soytürk M, et al. Validity and diagnostic ability of pancreatic exocrine insufficiency questionnaire (PEI-Q) in Turkish patients. Turk J Gastroenterol. 2024;35(9):735-742.
- 15 September 2024
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 35 (9) , 735-742
Open AccessValidity and Diagnostic Ability of Pancreatic Exocrine Insufficiency Questionnaire in Turkish Patients
Background/Aims: Pancreatic exocrine insufficiency (PEI) is a prevalent disease that is often underdiagnosed and undertreated, leading to resulting in diminished health-related quality of life. The PEI questionnaire (PEI-Q), a patient-reported outcome questionnaire developed to diagnose and evaluate PEI, is available only in English. The study aimed to provide a Turkish translation of PEI-Q and validate its reliability and diagnostic performance in a Turkish-speaking population with PEI. Materials and Methods: This study included 161 participants: 98 patients with PEI and 63 healthy controls. Participants underwent the PEI-Q test, and the results were statistically analyzed for reliability and validity. The diagnostic value of PEI-Q was determined using receiver operating characteristic (ROC) curves. Cronbach’s alpha was used to assess internal consistency, while exploratory factor analysis was performed to determine construct validity and reveal the factor structure. Results: The mean age of participants was 45.0 years, and 60.2% were male. Participants with PEI were significantly older than those without. Scores for abdominal, bowel movement, and total symptoms were significantly higher in patients with PEI than in controls. ROC analysis revealed good diagnostic value for PEI-Q, with areas under the curve ranging from 0.798 to 0.851 for different symptom scores. Cronbach’s alpha coefficients were above 0.70, indicating good internal consistency, and exploratory factor analysis supported a 4-factor structure, accounting for 68.9% of the total variance. Conclusion: The Turkish version of the PEI-Q is a reliable, easy-to-use, and valid screening tool for diagnosing PEI. It consistently assesses symptoms and quality of life in patients with PEI, helping to inform diagnosis and treatment. Cite this article as: Oğuz D, Kalkan İH, Soytürk M, et al. Validity and diagnostic ability of pancreatic exocrine insufficiency questionnaire (PEI-Q) in Turkish patients. Turk J Gastroenterol. 2024;35(9):735-742.
- Open Access
- 30 November 2023
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 1 (4) , 96-101
The relationship between hepatocellular carcinoma and Resolvin D1
Aims: Liver cancer is the second most common cause of cancer death, and hepatocellular carcinoma (HCC) is the most common hepatic primary tumor. Hepatocellular carcinoma develops based on inflammation in the cirrhotic liver. The aim of our study was to determine the relationship between the decrease in Resolvin D1, the lipid mediator involved in the resolution, and hepatocarcinogenesis. Methods: Thirty patients with HCC, thirty patients with cirrhosis, and thirty healthy subjects followed in our clinic between March 2018 and June 2019 were included in the study. Routine laboratory test results of the patients were recorded from the institutional database. Resolvin D1 and other parameters of the study groups were compared. Results: The Resolvin D1 levels were found to be significantly different from each other group, with the ranking as follows: the HCC group (1.71 ± 1.46 ng/ml)< the cirrhotic group (3.63 ± 2.92 ng/ml)< the healthy control group (6.24 ± 3.18 ng/ml). Moreover, Resolvin D1 levels were negatively correlated with ?-fetoprotein (AFP) level and tumor stage. Conclusion: Reduced lipid mediators that aid in the resolution process cause an increase in pro-inflammatory cytokines involved in the development of hepatocellular carcinoma. A decrease in Resolvin D1 may serve as a biomarker contributing to the diagnosis of progression to HCC in cirrhotic patients by triggering chronic inflammation and hepatocarcinogenesis.
- 30 November 2023
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 1 (4) , 96-101
Open AccessThe relationship between hepatocellular carcinoma and Resolvin D1
Aims: Liver cancer is the second most common cause of cancer death, and hepatocellular carcinoma (HCC) is the most common hepatic primary tumor. Hepatocellular carcinoma develops based on inflammation in the cirrhotic liver. The aim of our study was to determine the relationship between the decrease in Resolvin D1, the lipid mediator involved in the resolution, and hepatocarcinogenesis. Methods: Thirty patients with HCC, thirty patients with cirrhosis, and thirty healthy subjects followed in our clinic between March 2018 and June 2019 were included in the study. Routine laboratory test results of the patients were recorded from the institutional database. Resolvin D1 and other parameters of the study groups were compared. Results: The Resolvin D1 levels were found to be significantly different from each other group, with the ranking as follows: the HCC group (1.71 ± 1.46 ng/ml)< the cirrhotic group (3.63 ± 2.92 ng/ml)< the healthy control group (6.24 ± 3.18 ng/ml). Moreover, Resolvin D1 levels were negatively correlated with ?-fetoprotein (AFP) level and tumor stage. Conclusion: Reduced lipid mediators that aid in the resolution process cause an increase in pro-inflammatory cytokines involved in the development of hepatocellular carcinoma. A decrease in Resolvin D1 may serve as a biomarker contributing to the diagnosis of progression to HCC in cirrhotic patients by triggering chronic inflammation and hepatocarcinogenesis.
- 13 October 2023
- Published by Elsevier in Pancreatology
- Vol. 24 (3) , 327-334
Acute pancreatitis in Turkey: Results of a nationwide multicenter study
- 13 October 2023
- Published by Elsevier in Pancreatology
- Vol. 24 (3) , 327-334
Acute pancreatitis in Turkey: Results of a nationwide multicenter study